Literature DB >> 23296131

The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects.

Alireza Minagar1, Michael H Barnett, Ralph H B Benedict, Daniel Pelletier, Istvan Pirko, Mohamad Ali Sahraian, Elliott Frohman, Robert Zivadinov.   

Abstract

The paired thalamic nuclei are gray matter (GM) structures on both sides of the third ventricle that play major roles in cortical activation, relaying sensory information to the higher cortical centers that influence cognition. Multiple sclerosis (MS) is an immune-mediated disease of the human CNS that affects both the white matter (WM) and GM. A number of clinical observations as well as recent neuropathologic and neuroimaging studies have clearly demonstrated extensive involvement of the thalamus, basal ganglia, and neocortex in patients with MS. Modern MRI techniques permit visualization of GM lesions and measurement of atrophy. These contemporary methods have fundamentally altered our understanding of the pathophysiologic nature of MS. Evidence confirms the contention that GM injury can be detected in the earliest phases of MS, and that iron deposition and atrophy of deep gray nuclei are closely related to the magnitude of inflammation. Extensive involvement of GM, and particularly of the thalamus, is associated with a wide range of clinical manifestations including cognitive decline, motor deficits, fatigue, painful syndromes, and ocular motility disturbances in patients with MS. In this review, we characterize the neuropathologic, neuroimaging, and clinical features of thalamic involvement in MS. Further, we underscore the contention that neuropathologic and neuroimaging correlative investigations of thalamic derangements in MS may elucidate not heretofore considered pathobiological underpinnings germane to understanding the ontogeny, magnitude, and progression of the disease process.

Entities:  

Mesh:

Year:  2013        PMID: 23296131      PMCID: PMC3589190          DOI: 10.1212/WNL.0b013e31827b910b

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  60 in total

1.  A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes.

Authors:  Antonia Ceccarelli; Maria A Rocca; Elisabetta Pagani; Bruno Colombo; Vittorio Martinelli; Giancarlo Comi; Massimo Filippi
Journal:  Neuroimage       Date:  2008-04-20       Impact factor: 6.556

2.  Damage to the optic radiation in multiple sclerosis is associated with retinal injury and visual disability.

Authors:  Daniel S Reich; Seth A Smith; Eliza M Gordon-Lipkin; Arzu Ozturk; Brian S Caffo; Laura J Balcer; Peter A Calabresi
Journal:  Arch Neurol       Date:  2009-08

3.  Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis.

Authors:  Roberta Magliozzi; Sandra Columba-Cabezas; Barbara Serafini; Francesca Aloisi
Journal:  J Neuroimmunol       Date:  2004-03       Impact factor: 3.478

Review 4.  Physiopathology of fatigue in multiple sclerosis.

Authors:  Letizia Leocani; Bruno Colombo; Giancarlo Comi
Journal:  Neurol Sci       Date:  2008-09       Impact factor: 3.307

5.  Extent of cerebellum, subcortical and cortical atrophy in patients with MS: a case-control study.

Authors:  Deepa Preeti Ramasamy; Ralph H B Benedict; Jennifer L Cox; David Fritz; Nadir Abdelrahman; Sara Hussein; Alireza Minagar; Michael G Dwyer; Robert Zivadinov
Journal:  J Neurol Sci       Date:  2009-02-06       Impact factor: 3.181

6.  Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden.

Authors:  Ralph H B Benedict; Bianca Weinstock-Guttman; Inna Fishman; Jitendra Sharma; Christopher W Tjoa; Rohit Bakshi
Journal:  Arch Neurol       Date:  2004-02

Review 7.  Meningeal and cortical grey matter pathology in multiple sclerosis.

Authors:  Bogdan F Gh Popescu; Claudia F Lucchinetti
Journal:  BMC Neurol       Date:  2012-03-07       Impact factor: 2.474

8.  Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis.

Authors:  L K Fisniku; D R Altmann; M Cercignani; D J Tozer; D T Chard; J S Jackson; K A Miszkiel; K Schmierer; A J Thompson; D H Miller
Journal:  Mult Scler       Date:  2009-05-12       Impact factor: 6.312

9.  Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes.

Authors:  Catherine M Dalton; Declan T Chard; Gerard R Davies; Katherine A Miszkiel; Dan R Altmann; Kryshani Fernando; Gordon T Plant; Alan J Thompson; David H Miller
Journal:  Brain       Date:  2004-03-03       Impact factor: 13.501

10.  Thalamic neurodegeneration in relapsing-remitting multiple sclerosis.

Authors:  M Wylezinska; A Cifelli; P Jezzard; J Palace; M Alecci; P M Matthews
Journal:  Neurology       Date:  2003-06-24       Impact factor: 9.910

View more
  102 in total

1.  Whole brain functional connectivity in clinically isolated syndrome without conventional brain MRI lesions.

Authors:  Yaou Liu; Zhengjia Dai; Yunyun Duan; Jing Huang; Zhuoqiong Ren; Zheng Liu; Huiqing Dong; Ni Shu; Hugo Vrenken; Mike P Wattjes; Frederik Barkhof; Yong He; Kuncheng Li
Journal:  Eur Radiol       Date:  2015-12-29       Impact factor: 5.315

2.  Connectivity-based parcellation of the thalamus in multiple sclerosis and its implications for cognitive impairment: A multicenter study.

Authors:  Alvino Bisecco; Maria A Rocca; Elisabetta Pagani; Laura Mancini; Christian Enzinger; Antonio Gallo; Hugo Vrenken; Maria Laura Stromillo; Massimiliano Copetti; David L Thomas; Franz Fazekas; Gioacchino Tedeschi; Frederik Barkhof; Nicola De Stefano; Massimo Filippi
Journal:  Hum Brain Mapp       Date:  2015-04-14       Impact factor: 5.038

3.  Visualization of intra-thalamic nuclei with optimized white-matter-nulled MPRAGE at 7T.

Authors:  Thomas Tourdias; Manojkumar Saranathan; Ives R Levesque; Jason Su; Brian K Rutt
Journal:  Neuroimage       Date:  2013-09-07       Impact factor: 6.556

4.  Determinants of Deep Gray Matter Atrophy in Multiple Sclerosis: A Multimodal MRI Study.

Authors:  G Pontillo; S Cocozza; R Lanzillo; C Russo; M D Stasi; C Paolella; E A Vola; C Criscuolo; P Borrelli; G Palma; E Tedeschi; V B Morra; A Elefante; A Brunetti
Journal:  AJNR Am J Neuroradiol       Date:  2018-12-20       Impact factor: 3.825

5.  Evidencing different neurochemical profiles between thalamic nuclei using high resolution 2D-PRESS semi-LASER (1)H-MRSI at 7 T.

Authors:  Maxime Donadieu; Yann Le Fur; Sylviane Confort-Gouny; Arnaud Le Troter; Maxime Guye; Jean-Philippe Ranjeva
Journal:  MAGMA       Date:  2016-04-08       Impact factor: 2.310

6.  Role of thalamic diffusion for disease differentiation between multiple sclerosis and ischemic cerebral small vessel disease.

Authors:  Bilge Öztoprak; İbrahim Öztoprak; Kamil Topalkara; Mustafa F Erkoç; İsmail Şalk
Journal:  Neuroradiology       Date:  2014-12-23       Impact factor: 2.804

7.  3T MRI Whole-Brain Microscopy Discrimination of Subcortical Anatomy, Part 2: Basal Forebrain.

Authors:  M J Hoch; M T Bruno; A Faustin; N Cruz; A Y Mogilner; L Crandall; T Wisniewski; O Devinsky; T M Shepherd
Journal:  AJNR Am J Neuroradiol       Date:  2019-06-13       Impact factor: 3.825

8.  Thalamus Optimized Multi Atlas Segmentation (THOMAS): fast, fully automated segmentation of thalamic nuclei from structural MRI.

Authors:  Jason H Su; Francis T Thomas; Willard S Kasoff; Thomas Tourdias; Eun Young Choi; Brian K Rutt; Manojkumar Saranathan
Journal:  Neuroimage       Date:  2019-03-17       Impact factor: 6.556

Review 9.  MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.

Authors:  Ulrike W Kaunzner; Susan A Gauthier
Journal:  Ther Adv Neurol Disord       Date:  2017-05-12       Impact factor: 6.570

10.  What Causes Deep Gray Matter Atrophy in Multiple Sclerosis?

Authors:  M M Schoonheim; J J G Geurts
Journal:  AJNR Am J Neuroradiol       Date:  2018-12-27       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.